Your session is about to expire
← Back to Search
FT516 for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer drug, FT516, to see if it is safe and effective when used alone or with other drugs to treat AML or B-cell lymphoma.
- Non-Hodgkin's Lymphoma
- Acute Myeloid Leukemia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a certain type of lymphoma that hasn't responded to previous treatments and there are no other treatments available that can help improve your survival.You are allergic to human albumin or DMSO.You have a type of blood cancer called acute myeloid leukemia (AML) that has come back after treatment attempts. If you are over 60 years old, you do not need to have previous re-treatment attempts.You have a serious heart condition that could affect your participation in the study.To provide accurate summaries, I would need the specific diagnoses mentioned in the criterion. Could you please provide the diagnoses?You will be receiving only one type of treatment called Regimen A (FT516).You are receiving a treatment called Regimen B, which includes FT516 and either rituximab or obinutuzumab.
- Group 1: FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning
- Group 2: FT516 in Combination with Monoclonal Antibodies
- Group 3: FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule
- Group 4: FT516 Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is the patient population engaged in this medical study?
"Indeed, the trial is still recruiting. According to clinicaltrials.gov, it was originally posted on October 4th 2019 and most recently updated on July 25th 2022. Currently 234 volunteers are needed across 7 different locations for this study."
Has the FDA sanctioned FT516 for use yet?
"The safety of FT516 has been given a rating of 1, owing to the limited amount of clinical data available regarding its efficacy and potential side effects. This is an early phase trial."
What are the known outcomes of prior FT516 studies?
"As of now, 1241 FT516 studies are ongoing with 238 in Phase 3. Most these trials take place in Philadelphia; however, there exist 41188 other sites conducting clinical research on this drug."
What medical purpose is FT516 typically employed for?
"FT516 is the most effective way to treat lung cancer and can be utilized to manage numerous other ailments like multiple sclerosis, b-cell lymphomas, and polyangium."
Is enrollment still open for participation in this research project?
"Indeed, according to the data accessible on clinicaltrials.gov this experiment is at present open for enrollment. Originally posted in October 4th 2019, it was recently refreshed on July 25th 2022. Approximately 234 volunteers must be recruited from 7 distinct sites."
How many healthcare locations are currently conducting this experiment in the state?
"Seven different clinical centres are taking part in this trial, with Seattle's Swedish Cancer Institute, Phoenix's Mayo Clinic, and Dallas' UT Southwestern being some of the leading sites. Additionally, four other locations have been recruited to take part."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger